Research Article

Course of Hyperkalemia in Patients on Hemodialysis

Figure 3

Proportion of placebo patients with predialysis sK+ ranges of 4.0–5.0 and 4.0–5.5 mmol/L for ≥1, ≥2, ≥3, and 4 LIDI visits during the 4-week evaluation period, by predialysis sK+ concentration at randomization. Predialysis sK+ measurement at randomization (visit 4, day 1) was used for subgroup stratification. Predialysis sK+ values obtained at the LIDI visits in the 4-week evaluation period. No imputation of missing data was conducted. Patients receiving rescue therapy were included in the analysis. LIDI, long interdialytic interval; sK+, serum potassium.